PP
MRNA icon

Paloma Partners’s Moderna MRNA Stock Holding History

Paloma Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,700
Closed -$439K – 1490
2024
Q2 		$439K Buy
+3,700
New +$468K 0.01% 803
2024
Q1 		– Sell
-13,900
Closed -$1.38M – 963
2023
Q4 		$1.38M Sell
13,900
-12,000
-46% -$1.01M 0.05% 345
2023
Q3 		$2.68M Sell
25,900
-10,300
-28% -$1.15M 0.09% 185
2023
Q2 		$4.4M Buy
36,200
+15,900
+78% +$2.12M 0.16% 123
2023
Q1 		$3.12M Buy
+20,300
New +$3.35M 0.11% 158
2022
Q4 		– Sell
-24,000
Closed -$2.84M – 1079
2022
Q3 		$2.84M Buy
+24,000
New +$3.64M 0.13% 138

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Paloma Partners's MRNA Position: Q4 2024 in Review

Paloma Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 4,768 shares — an estimated $319K sold.

Paloma Partners first reported a position in MRNA in Q4 2019 and held it in 12 quarters. The position peaked at $3.86M in Q2 2020. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Paloma Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 4,768 Moderna shares in Q4 2024, an estimated $319K.
  • Paloma Partners first reported a position in Moderna in Q4 2019 and held it in 12 quarters.
  • Paloma Partners's Moderna position peaked at $3.86M in Q2 2020.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.